ZyVersa Therapeutics, Inc.
OTC: ZVSA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stephen C. Glover
- Employees
- 7
- Headquarters
- Weston, United States
- IPO year
- 2022
- Market cap
- $1.4M
- Website
- https://www.zyversa.com
Loading ZVSA…
Loading profile data…Frequently asked questions about ZVSA
What does ZyVersa Therapeutics, Inc. (ZVSA) do?
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomeruloscle...
Where does ZVSA trade?
ZyVersa Therapeutics, Inc. (ZVSA) trades on the Other OTC.
What sector is ZVSA in?
ZyVersa Therapeutics, Inc. (ZVSA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ZyVersa Therapeutics, Inc.?
Stephen C. Glover is the chief executive officer of ZyVersa Therapeutics, Inc. (ZVSA).
Where is ZyVersa Therapeutics, Inc. headquartered?
ZyVersa Therapeutics, Inc. is headquartered in United States.
Does ZVSA pay a dividend?
ZyVersa Therapeutics, Inc. (ZVSA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ZVSA go public?
ZyVersa Therapeutics, Inc. (ZVSA) completed its initial public offering in 2022.